Skip to content

Valneva

  • About Us
    About Us Advancing vaccines for better lives Learn More
    • Our Strategy
    • Our Responsibility
    • Our Team
  • Products
    Products Focusing on vaccines for infectious diseases with major unmet needs. Learn More
    • Japanese Encephalitis Vaccine
    • Cholera Vaccine
    • Marketing and Distribution
    • Manufacturing and Services
  • R&D
    R&D Dedicated to innovation in vaccine research and development. Learn More
    • Pipeline
    • Lyme Disease – VLA15
    • Chikungunya – VLA1553
    • COVID-19 – VLA2001
    • Zika – VLA1601
    • Clostridium Difficile – VLA84
    • Scientific Publications
  • Investors
    Investors Learn More
    • Financial & Filings
      • Financial Reports
      • Annual General Meeting 2020
      • Extraordinary General Meeting 2020
      • General Meeting Archive
    • Press Releases
    • Corporate Governance
      • Corporate Governance
      • Corporate Compliance & Ethics
    • Regulated Information
    • Stock Information
      • Stock Price
      • Analysts
      • Shareholder Structure
      • Vienna Stock Exchange Delisting
    • Events and Presentations
      • Calendar
      • Corporate Presentations
    • Videos and Webcasts
    • Contact
  • Media
    Media Press releases, latest news and media resources Learn More
    • Press Releases
    • In The News
    • Media Kit
    • Media Contact
  • Careers
Contact
  • EN
  • FR
Search

Press Releases

February 1, 2021

Valneva Announces UK Government Exercise of Option for 40 Million Doses of its Inactivated, Adjuvanted COVID-19 Vaccine

January 28, 2021

Valneva Commences Manufacturing of its Inactivated, Adjuvanted COVID-19 Vaccine, Completes Phase 1/2 Study Recruitment

January 25, 2021

Valneva and Instituto Butantan Sign Final Agreement on Single-Shot Chikungunya Vaccine for Low and Middle Income Countries

January 15, 2021

Valneva Announces Amendment to Deerfield and OrbiMed Debt Facility Terms

January 12, 2021

Valneva in Advanced Discussions with European Commission to Supply up to 60 Million Doses of Inactivated, Adjuvanted COVID-19 Vaccine Candidate

January 11, 2021

Valneva Strengthens Management Team; Appoints Perry Celentano as Interim COO and David Lawrence as Acting CFO

January 7, 2021

Valneva Reports FY 2020 Cash of Over €200 Million

December 22, 2020

Valneva Shareholders Approve EGM Resolutions to Support Potential US IPO Plan

December 16, 2020

Valneva Initiates Phase 1/2 Clinical Study of Inactivated, Adjuvanted COVID-19 Vaccine Candidate

December 7, 2020

Valneva Announces the Modification of the Conditions of Participation in its Extraordinary General Meeting of December 22, 2020, which will be held as a closed meeting

  • 1
  • 2
  • 3
  • 4
  • …
  • 37

Valneva

  • About Us
  • Products
  • R&D
  • Investors
  • Media
  • Careers
Related Websites
  • Valneva Canada
  • Valneva UK
  • Valneva Austria
  • Valneva USA
  • Valneva Nordic
  • Valneva France
Contact
© 2021 Valneva SE. All rights reserved.
  • Legal Notice
  • Cookie Policy
  • Privacy Policy
  • Terms of Use
  • 1907-00-VLA-002 | 11-JUL-2019
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Cookie settingsACCEPT Reject
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are as essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled

Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.

Non-necessary

Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.

SAVE & ACCEPT